Monday, April 8, 2019
Applying AI to Save Lives During the Opioid Crisis
The U.S. is in the throes of a devastating epidemic of opioid addiction and overdose — some 130 people die nationally every day from opioids, says the National Institute on Drug Abuse. With a total economic cost of more than $78 billion a year, AI is being harnessed to develop new tools that can help alleviate this national crisis. This session will discuss AI-based strategies that academic and industry teams are leveraging to help clinical and public health officials better predict, identify, and treat opioid addiction, and also data privacy concerns.
Moderator: Thomas Sequist, MD, Chief Quality & Safety Officer, PHS
Bob Burgin, CEO, Amplifire Healthcare Alliance
Carm Huntress, CEO, RxRevu Inc
Sarah Wakeman, MD, Medical Director, Substance Use Disorder Initiative, MGH; Assistant Professor, Medicine, HMS
Scott Weiner, MD, Director, Brigham Comprehensive Opioid Response and Education (B-CORE) Program, BH; Assistant Professor, HMS
Community Hospitals: Key Component in Healthcare Transformation
Community hospitals are the largest sources of patient care in the U.S. As such, they represent a frontier in the transformation of health care. How are these organizations using AI and digital technologies to drive transformation? What are the distinctions from academic medical centers? This session will address these and other topics that impact community hospitals.
Moderator: Michael Jaff, DO, President, NWH, PHS, Professor of Medicine, HMS
Fabien Beckers, PhD, CEO, Arterys
Joanna Geisinger, CEO, TORq Interface
John Miller, MD, Director, Retinal Imaging, MEE; Assistant Professor, Ophthalmology, HMS
Lee Schwamm, MD, Director, Center for TeleHealth and Exec Vice Chair, Neurology, MGH; Professor, Neurology, HMS
Tal Wenderow, CEO, Beyond Verbal
Digital Management of Diabetes
Across the spectrum of patient care, the management of diabetes has been flooded with new technology and treatment options for both type 1 and type 2 diabetes – there is a range of new devices and software, including automatic insulin infusion systems, glucose sensors, AI-based algorithms and decision support tools, with an artificial pancreas on the horizon. This session will focus on these areas and clinical use cases that highlight the value of AI.
Moderator: Deborah Wexler, MD, Clinical Director, Diabetes Center, MGH; Associate Professor, HMS
Marie McDonnell, MD, Section Chief and Director, Diabetes Program, BH; Lecturer, HMS
Michael Meissner, PhD, CTO and VP, MED, Sanofi
Joshua Riff, MD, CEO, Onduo
Marie Schiller, VP, Connected Care and Insulins Product Development and Site Head, Cambridge Innovation Center, Eli Lilly
AI and Its Impact on the Future of Emergency Care
There are over 136 million Emergency Department visits annually in the U.S. providing 24/7 unscheduled treatment for problems from minor illness to life threatening traumatic injuries. Emergency department care teams provide high quality, safe care in an efficient fashion. In this session, we consider the future of AI in emergency care from the initial decision to seek emergency care, to diagnostic processes within the ED and final disposition decision.. From chat bots for patient triage, telehealth for patient visits to machine learning outcome prediction, we will consider how these novel technologies will impact emergency care delivery.
Moderator: Adam Landman, MD, VP and CIO, BH; Associate Professor of Emergency Medicine, HMS
Peter Chai, MD, Assistant Professor, Emergency Medicine, BH, HMS
Emily Hayden, MD, Attending Physician, Emergency Medicine, MGH; Instructor, Surgery, HMS
Kohei Hasegawa, MD, Attending Physician, Emergency Medicine, MGH; Associate Professor, Emergency Medicine, HMS
Sean Kelly, MD, CMO, Imprivata; Assistant Professor, Emergency Medicine, HMS
Bijoy Sagar, VP, Chief Digital Technology Officer, Stryker
Mental Health, Smartphone Apps and the Promise of AI
Patients can face significant barriers when it comes to accessing high-quality, evidence-based treatment for mental illness. AI-enabled technologies, including smartphone-based tools, that may help close this treatment gap for patients worldwide. This session will focus on efforts to develop smartphone apps and other tools, including those designed to help predict patients’ moods and provide cognitive behavioral therapy.
Moderator: Sabine Wilhelm, PhD, Chief of Psychology; Director, OCD and Related Disorders Program, MGH; Professor, Psychology, HMS
Jennifer Gentile, PsyD, SVP, US Clinical Operations, Ieso Digital Health
Thomas McCoy, MD, Director of Research, Center for Quantitative Health, MGH; Assistant Professor, Psychiatry and Medicine, HMS
Christopher Molaro, CEO, Neuroflow
David Silbersweig, MD, Chairman, Department of Psychiatry, BH; Stanley Cobb Professor of Psychiatry, HMS
Jeremy Sohn, VP, Global Head of Digital Business Development and Licensing , Novartis
From Startup to Impact (Pharma and Diagnostics)
This session will introduce you to five leading start-up companies who will each share their respective impact in the pharmaceutical and diagnostic realms in 10-minute pitches.
Moderator: James Brink, MD, Radiologist-in-Chief, MGH; Juan M. Taveras Professor of Radiology, HMS
Moderator: James Nicholls, Managing Director, Fitzroy Health
Sarah Beeby, EVP, GM Lifesciences, Clinithink
Charles Cadieu, PhD, CEO, Bay Labs
JB Michel, PhD, SVP Data Science & GM USA, BenevolentAI
Art Papier, MD, CEO, VisualDx
Alex Zhavoronkov, PhD, CEO, Insilico Medicine, Inc
As the potential of AI comes into clearer view, many academic medical centers are taking notice and crafting institutional strategies for incorporating AI into clinical practice. But where are the most meaningful opportunities? What are the biggest challenges? And, importantly, will patient care be noticeably different — better, more available, and/or less costly?
AI is a tool for conducting faster, more efficient clinical trials. Panelists will discuss how AI-enabled methods can further adaptive trial capabilities, trial design and trial management.
As providers embrace value-based approaches, the demands of clinical data collection, assessment, and information-sharing loom large. In this data-driven environment, clinicians must sift through ever-growing pools of information that can exceed the limits of human capability. An assortment of AI-based solutions is now emerging that may offer some relief. Panelists will discuss how these approaches are helping to support better, more personalized care, and the challenges faced by clinicians and managers for effective adoption.
Cardiovascular diseases remain the leading cause of death worldwide and an expense, making this area ripe for AI-enabled innovations. Teams are pursuing a range of AI-based tools in cardiovascular medicine: including AI-powered drug discovery and diagnostics to automated cardiac image analyses and AI-guided care delivery pathways. Panelists will discuss where AI is having a sizeable impact. The discussion will also include the perspectives of a patient who benefited from AI-enabled cardiovascular care.
Tuesday, April 9, 2019
With AI-enabled care strategies and digital technologies, clinicians and patients are embracing new approaches to improve the lives of cancer patients through enhanced diagnosis and treatment. These include AI-guided tools for more precise methods of predicting risk, more effective screening strategies, patient data driven insights and more personalized treatments. Panelists will engage on how these and other innovations are enabling a new era of cancer care.
In 1984 Isaac Asimov was asked to predict what life in 2019 would be like. Using the same aperture, we as what will constitute health care 35 years from now? Current trends suggest that there will be significant gains in immunotherapy, gene therapy, and breakthrough treatments for neurologic, cardiovascular and oncologic diseases. Panelists will draw on their visionary perspective and will reflect on what to expect and why.
Chief executives share perspectives on the impact of AI on their respective companies and industry segments. Panelists will discuss their views of AI, how AI figures into their organizations’ current product and investment strategies, and how they are measuring return on existing AI investments. The panel will also address opportunities and challenges surrounding AI, ranging from workforce needs to managing bias in AI development.
Provider Back Office of the Future
The application of AI-based technologies to the business side of health care — including functions such as billing, payment, and insurance claims management — could lead to significant improvements in health care operations and efficiency, with billions of dollars in savings each year. Panelists will discuss emerging tools and technologies as well as the opportunities and pitfalls of using AI to innovate and automate back office functions.
Moderator: Peter Markell, EVP, Administration and Finance, CFO and Treasurer, PHS
Ingeborg Garrison, CNO/VP of Strategic Advisory Services, Verge Health
Kent Ivanoff, CEO, VisitPay
Mary Beth Remorenko, VP, Revenue Cycle Operations, PHS
Brian Robertson, CEO, VisiQuate
Chief Digital Strategy Officer Roundtable
With the advent of AI-enabled technologies, this session brings together leading chief digital health officers. The discussion will address tradeoffs in sequencing technology across academic medical centers; what technologies are being prioritized; and consumer expectations.
Moderator: Alistair Erskine, MD, Chief Digital Health Officer, PHS
Michael Anderes, Chief Innovation and Digital Health Officer, Froedtert Health; President, Inception Health
Adam Landman, MD, VP and CIO, BH; Associate Professor of Emergency Medicine, HMS
Aimee Quirk, CEO, innovationOchsner
Richard Zane, MD, Chief Innovation Officer, UCHealth; Professor and Chair,Department of Emergency Medicine, University of Colorado School of Medicine
Innovation Fellows: A New Model of Collaboration
The Innovation Fellows Program provides experiential career development opportunities for future leaders in health care. It facilitates personnel exchanges between Harvard Medical School staff from Partners’ hospitals and participating biopharmaceutical, device, venture capital, digital health, payor and consulting firms. Fellows and Hosts learn from each other as they collaborate on projects ranging from clinical development to digital health and artificial intelligence. Learn how this new model of collaboration can deliver value and lead to broader relationships between industry and academia.
Moderator: Seema Basu, PhD, Market Sector Leader, Innovation, PHS
Nathalie Agar, PhD, Research Scientist, Neurosurgery, BH; Associate Professor, Neurosurgery, Radiology, HMS
Paul Anderson, MD, PhD, Chief Academic Officer, BH; SVP, Research, BH; K. Frank Austen Professor of Medicine, HMS
Laurie Braun, MD, Partners Innovation Fellow, MGH and Boston Pharmaceuticals; Instructor in Pediatrics, HMS
David Chiang, MD, PhD, Research Fellow, BH; Innovation Fellow, Boston Scientific
David Feygin, PhD, Chief Digital Health Officer, Boston Scientific
Peter Ho, MD, PhD, CMO, Boston Pharmaceuticals
Harry Orf, PhD, SVP, Research, MGH; Principal Associate, HMS
Last Mile: Fully Implementing AI in Healthcare
This session will focus on how radiology and pathology specialties are currently applying AI in the clinic. Where will it be built out first? What are the barriers and how will these challenges be overcome?
Moderator: Keith Dreyer, DO, PhD, Chief Data Science Officer, PHS; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS
Katherine Andriole, PhD, Director of Research Strategy and Operations, MGH & BWH CCDS; Associate Professor, Radiology, HMS
Samuel Aronson, Executive Director, IT, Personalized Medicine, PHS
Peter Durlach, SVP, Healthcare Strategy & New Business Development, Nuance
Seth Hain, VP of R&D, Epic
Jonathan Teich, MD, PhD, Chief Medical Information Officer, InterSystems; Emergency Medicine, BH
Reimagining Disease Management
The management of disease has become vastly more challenging, both for patients and providers. AI-based technologies promise to improve and streamline patient care through a variety of approaches. This session will feature a discussion of these new tools and how they can enhance patient engagement and optimize care management.
Moderator: Sree Chaguturu, MD, Chief Population Health Officer, PHS; Assistant Professor, Medicine, HMS
Murray Brozinsky, Chief Strategy Officer, Conversa
Jean Drouin, MD, CEO, Clarify Health Solutions
Julian Harris, MD, President, CareAllies
Erika Pabo, MD, Chief Health Officer, Humana Edge; Associate Faculty, Ariadne Labs; Associate Physician, BH; Instructor, HMS
Standards and Regulation: The Emerging AI Framework
As the health care industry faces an explosion of AI-based tools, the FDA’s approach to these technologies is evolving. This session will focus on the agency’s approach to AI-based products, how to calculate the risk profile of these new technologies, and the challenges of securing adequate data rights.
Moderator: Brent Henry, Member, Mintz Levin
Bethany Hills, Member/ Chair, FDA Practice, Mintz Levin
Michelle McMurry-Heath, MD, PhD, VP, Global Regulatory Affairs and International Clinical Evidence, Johnson & Johnson Medical Devices
Bakul Patel, Associate Director, Digital Health, FDA
Michael Spadafore, Managing Director, Sandbox Industries
From Startup to Impact (Provider Solutions)
This session will introduce you to five leading startup companies who will each share their respective impact in delivery provider solutions in ten-minute pitches.
Moderator: Meredith Fisher, PhD, Partner, Partners Innovation Fund, PHS
Moderator: James Stanford, Managing Director, Fitzroy Health
William Grambley, COO, AllazoHealth
Gal Salomon, CEO, CLEW
Brian Symmons, COO, Gauss Surgical
Pelu Tran, CEO, Ferrum Health
Ed Zecchini, CIO, Remedy Partners
China’s health care system faces major challenges — and its population is aging more rapidly than nearly every other country. To help address these problems, the Chinese health technology sector is strongly embracing AI. What are the most exciting applications? What lessons does China’s early forays into AI-enabled patient care hold for other health care systems?
The billions invested worldwide in AI-based health care technologies underscore the enthusiasm of global investors. But where are the greatest opportunities and what is the timeline to meaningful impact? In this panel, venture, private equity investors, and buy side analysts will discuss investment priorities, timelines, and key areas of interest
Al is powering a revolution in consumer health care, giving patients a deeper role in monitoring their own health and spawning new models of care delivery. Many health care organizations are increasingly focused on creating a digital “front door” for patients – a single gateway to mobile apps and other online services. Panelists will also discuss the role of remote monitoring and virtual care programs as well as the role of Al in care redesign and workflow.
Wednesday, April 10, 2019
Eleven clinical teams selected to receive highly competitive Innovation Discovery Grants present their work illustrating how AI can be used to improve patient health and health care delivery. This session is designed for investors, entrepreneurs, investigators, and others who are interested in commercializing AI opportunities that are currently in development with support from the Innovation Office.
To view speakers and topics, click here.
In the quest for effective treatments aimed at devastating neurological diseases like Alzheimer’s and ALS, there is a critical need for robust methods to predict and monitor disease progression. AI-based approaches offer promise in this important area. Panelists will discuss efforts to map movement-related disorders and use machine learning to predict the path of disease with imaging and biomarkers.
The Disruptive Dozen identifies and ranks the AI technologies that Partners faculty feel will break through over the next year to significantly improve health care.